MIRA Pharmaceuticals, an innovative pre-clinical-stage pharmaceutical company focused on the treatment of neurologic and neuropsychiatric disorders, today provided a corporate and operational update.
MIRA Pharma Announces Ketamir-2's Oral Bioavailability Predicted to be 80%